Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Targeting the PD1 and PDL1 immune checkpoint axis has paved the way for a new era of clinical care in cancer. Of the existing immuno-oncology (IO) agents in clinical development, anti-PD1 and anti-PDL1 monoclonal antibodies (mAbs) have achieved the most success. Indeed, there are ten approved anti-PD1/PDL1 mAbs in the global market, six of which are approved by the FDA. To date, these mAbs have garnered a total of 67 FDA approvals across 17 different cancer types and two tissue-agnostic conditions. This report summarizes the current landscape of anti-PD1/PDL1 mAb clinical trials and the challenges in patient recruitment.
